T he cellular proto-oncogene v-Myc myelocytomatosis viral oncogene homolog (c-MYC) was first identified as a cellular proto-oncogene in Burkitt lymphoma, a high-grade mature Bcell malignancy that expresses high levels of c-MYC as a result of chromosomal translocations (1) . Chromosomal alterations resulting in increased expression of c-MYC also were found in other B-cell malignancies, including diffuse large B-cell lymphoma (2) and multiple myeloma (3) . In rare cases of chronic lymphocytic leukemia (CLL), c-MYC translocations were found associated with progressive disease and poor prognosis (4) .
Mouse models with dysregulated expression of c-Myc at various stages of B-cell development have been generated, including Eμ-Myc (5), iMyc Eμ and iMyc Cμ mice and mice bearing a c-Myc transgene controlled by an Ig-alpha heavy-chain enhancer (iMyc Cα mice) (6) . These transgenic strains develop either immature B-cell lymphomas (Eμ-Myc mice) (5), Burkitt lymphoma-like disease (iMyc Eμ mice) (6) , or plasmacytic malignancies (iMyc Eμ mice) (6) . Apparent exceptions are iMyc Cα mice, in which only a small proportion of aged animals (≤ 9%) develop lymphomas (7) . Instead, these mice have poor antibody responses caused by the high turnover rates of plasma cells and memory B cells. B-cell activating factor of the tumor necrosis family (BAFF or CD257) failed to slow the turnover rates of plasma cells. Effect(s) of BAFF on memory B cells of these animals was not examined. BAFF interacts with three B-cell receptors, B-cell maturation (BCMA), activator and calciummodulator and cyclophilin ligand interactor (TACI), and BAFF-R (BR3), and triggers activation of IκB kinase (IKK)/NF-κB (8) . Consequently, Baff transgenic (Baff-Tg) mice have reduced turnover rates of mature and marginal-zone B cells (9, 10) , and aged mice develop a lupus-like autoimmune disease (9, 11) .
In a prior study (12) , we found that Eμ-TCL1/Baff-Tg mice had accelerated rates of leukemogenesis because of reduced rates of spontaneous B-cell apoptosis relative to Eμ-TCL1-Tg mice. Conceivably, the progeny of iMyc Cα -Tg mice mated with Baff-Tg mice might have reduced turnover rates of memory B cells because of increased expression of Myc from the iMyc Cα transgene. Reduced rates of cell death in the setting of perpetual cell proliferation could give rise to leukemia resembling human CLL, which apparently is derived from memory-type, antigenexperienced B cells (13, 14) .
Results
Myc/Baff-Tg Mice Develop Aggressive CLL-Like Disease. To evaluate the oncogenic effect of the c-MYC-BAFF interaction, we crossed iMyc Cα -Tg (Myc) mice, in which c-MYC is under control of the Ig Eα enhancer (7), with Baff-Tg mice, in which BAFF is produced by the liver (9) . Male Myc/Baff-Tg mice developed lymphocytosis at age 3 mo because of increased blood B-cell number relative to that noted for WT, single-Tg mice, or female double-Tg mice ( Fig. S1 A-C 1B) . Wright-Giemsa staining of blood smears showed excessive numbers of well-differentiated lymphocytes admixed with smudge cells, a feature resembling human CLL (Fig. S2A) . The median life span of male Myc/Baff mice was 10 mo, significantly shorter than that of Myc or Baff mice (Fig. 1C ).
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Increased
18 F-labeled 2-fluoro-2-deoxy-D-glucose (FDG) uptake is observed at tumor-infiltrating sites in ≈33% (19 of 57) of CLL cases (15) . To examine FDG uptake in leukemic mice, we performed an FDG-PET scan on 12-mo-old Myc and Myc/Baff male mice. Myc/Baff mice showed three times greater splenic FDG uptake than Myc mice ( Fig. 2A) , suggesting elevated leukemic cell metabolism. Splenomegaly was obvious in Myc/Baff mice after 4 mo of age, and the average weight of Myc/Baff spleens at 8 mo was 2.6-fold higher than Baff or Myc spleens and 5.2-fold higher than WT spleens (Fig. 2B) . H&E staining of splenic sections of 8-mo-old mice exhibited significantly enlarged white pulp in Myc/Baff mice with loss of normal splenic architecture resulting from a diffuse infiltration of mature lymphocytes (Fig. 2C) . As in the blood smears (Fig. S2A) , the majority of splenocytes in Myc/Baff mice showed features typical of welldifferentiated B cells, with very sparse cytoplasm and round nuclei (Fig. S2B) 
CD3
− leukemia cells were those with relevance to human CLL, including elevated expression of the antiapoptotic Bcl-2 family members Bcl2, Mcl1, and A1, decreased expression of death receptor Fas, marked elevation in IL-10, IL-5 receptor α, IL-6 signal transducer, and TNF super family member 8, as well as signatures of aggressive CLL, such as Ctla-4 and Zap70 (Fig. S3) . We confirmed these findings by quantitative PR-PCR (qRT-PCR) analyses (Fig. 3A and Fig. S3B ). Protein expression of Bcl-2 family members, including Bcl-2, Bcl-xL, Mcl-1, and A1, was examined by immunoblot (Fig. 3B) . We also looked for differences in expression of predefined gene sets by Gene Set Enrichment Analyses (GSEA) (16 − leukemia cells were five apoptosis-related and 18 stress-induced (including UV, chemical, virus infection) gene sets, further underscoring the antiapoptotic role of BAFF (Fig. S3C) . As a major target for BAFF signaling, the NF-κB gene set also was enriched in Myc/Baff CD5 + CD3
− leukemia cells (Fig.  S3C) . This finding is supported by immunoblot analysis of nuclear extracts, which showed that B cells from Baff mice or leukemia cells from Myc/Baff mice exhibited elevated levels of nuclear RelA, RelB, and p52, relative to B cells from WT or Myc mice (Fig. 3C) . Proliferation gene sets also were elevated in Myc/Baff CD5 + CD3 − leukemic cells (Fig. S3C) .
Because only double-Tg mice developed leukemia, we investigated whether constant BAFF exposure increased leukemia-cell proliferation or survival. Staining blood mononuclear cells for Ki-67 was performed to examine for proliferating T cells (CD3 (Fig. S4A and Fig. 3D ).
TUNEL staining of splenic sections revealed that Myc mice had four times more apoptotic cells in their spleens than Myc/Baff mice, suggesting that BAFF promotes B-cell expansion, at least in part, by inhibiting apoptosis of leukemic cells (Fig. S4B and Fig.  3E ). Compared with normal T or B cells, the CD5 + CD3 − B220 low cells of Myc/Baff mice had higher proportions of cells undergoing apoptosis; these proportions could be reduced by incubation with BAFF (Fig. 3F) . Collectively, these data suggest that BAFF promotes leukemogenesis in part by inhibiting apoptosis associated with dysregulated expression of c-MYC.
BAFF Stimulates c-Myc RNA and Protein Expression. Array analysis revealed that c-Myc mRNA was elevated in leukemia cells from Myc/Baff mice relative to that in B cells from Myc mice (Fig. 4A , Left). These findings were confirmed by qRT-PCR analysis (Fig.  4A , Right), suggesting that constitutive BAFF signaling enhances c-Myc transcription or mRNA stability. c-Myc protein also was elevated in Myc/Baff leukemia cells relative to levels in B cells from single-Tg Myc mice (Fig. 4B) . Similar results were observed in human primary CLL cells. BAFF treatment induced c-MYC RNA in most (8 of 10) CLL cells expressing low levels of MYC and in only a few (two of eight) high-MYC expressors (Fig. S5A) . BMS345541, a specific IKKβ inhibitor, blocked the capacity of BAFF to induce c-MYC in CLL cells (Fig. 4C) . IKK-dependent elevation of c-MYC was confirmed at the protein level (Fig. 4D) . BMS345541 also could inhibit BAFF-induced IκBα degradation or RelA nuclear translocation (Fig. S5B) . Consistently, silencing IKKβ with shRNA in primary CLL cells blocked BAFF-induced expression of c-MYC (Fig. 4E) . In addition, ChIP revealed that BAFF induced binding of RelA/ p65 to two of the predicted NF-κB consensus-binding sites of c-MYC promoter in two independent human primary CLL samples (Fig. 4F, and Fig. S5C ).These data suggest that BAFF prevents CLL cells from undergoing apoptosis through activation of NF-κB which, in addition to up-regulating antiapoptotic genes, also up-regulates expression of c-MYC. − B cells from 6-mo-old donors did not manifest clonal expansion in Baff mice, although we were able to detect CD5 + CD3 − B cells in the blood of Baff recipients from 2 wk to 9 mo after cell transfer (Fig. S6A) . However, transfer of CD5 + CD3 − leukemic cells from 12-mo-old donors resulted in CLL-like disease in Baff-Tg recipients (Fig.  S6B) , which developed enlarged spleens 5 wk after transfer (Fig.  S6C) . CD5 + CD3 − leukemic cells were found in spleen, lymph nodes, and marrow of Baff recipients (Fig. S6D) , which died 5-8 wk after transfer.
c-MYC Expression in CLL Correlates with Disease Progression and
Dependency on Nurse-Like Cells. We interrogated the Affymetrix array data obtained by analysis of CLL cells of 166 patients and observed a broad distribution in relative levels of c-MYC mRNA expression (Fig. 5A) . Differences in c-MYC RNA and protein were confirmed by qRT-PCR and immunoblot analyses (Fig. S7) . We examined the relationship between c-MYC expression and the time from diagnosis to initial therapy, a parameter that correlates with disease progression (18) . The median time from diagnosis to initial treatment for the patients whose CLL cells expressed the highest amounts of c-MYC mRNA was 4.01 y (n = 31), significantly shorter than that of patients with CLL cells that contained intermediate amounts of c-MYC mRNA (6.51 y, n = 75) or patients with CLL cells that had low levels c-MYC mRNA (9.01 y, n = 60) (Fig. 5B) . These data suggest that elevated c-MYC expression in CLL cells is associated with progressive disease requiring early therapy.
Consistent with previous findings that c-MYC promotes proliferation as well as apoptosis, human CLL cells that expressed high levels of c-MYC exhibited accelerated death in culture relative to CLL cells with low c-MYC (Fig. 5C ). The relatively high turnover rates of cells that express c-MYC might be mitigated by survival factors supplied by accessory cells in lymphoid tissues that comprise the leukemia cell microenvironment. The lymphoid tissue contains nurse-like cells (NLC), which express and secrete BAFF, a proliferation-inducing ligand (APRIL), and other factors that can enhance the resistance of CLL cells to apoptosis (19, 20) . When CLL cells were cocultured with NLC, CLL cells that expressed high levels of c-MYC had a marked dependency on NLC for survival, whereas CLL cells with low levels of c-MYC were less NLC-dependent (Fig. 5D ). Nearly all (15 of 17) the CLL samples that expressed high levels of c-MYC were dependent on NLC for survival, whereas only 32% (7 of 22) of CLL samples that expressed low levels of c-MYC displayed such dependency (P = 0.001) (Fig. 5D ). Treatment with a BR3-Fc fusion protein, a BAFF decoy receptor (21) , inhibited the capacity of NLC to protect CLL cells from apoptosis, particularly CLL cells that express high levels of c-MYC (Fig. 5E) . These results reveal that CLL cells that express high levels of c-MYC have an enhanced dependency on BAFF and NLC for survival.
Inhibition of IKK Signaling Decreases Viability of Mouse and Human
Leukemic Cells and Reduces Disease Burden. Inhibition of classical NF-κB signaling can trigger rapid death of human CLL cells in vitro (8) . Congruently, inhibition of IKKβ reduced the viability of both mouse leukemic cells and human CLL cells cocultured with NLC (Fig. S8A) . The IKKβ inhibitor BMS345541 was more cytotoxic for leukemic cells than for normal T cells or B cells (Fig.  S8A) . Human CLL cells expressing a high level of c-MYC also appeared more sensitive to BMS345541 than CLL cells with low levels of c-MYC when cocultured with NLC (Fig. S8B) .
To examine the antileukemia effect of IKKβ inhibition in vivo, we transferred 2 × 10 6 CD5 + CD3 − leukemic cells into Baff-Tg mice (Fig. S8C) . BMS345541 was administered by oral gavage at 4 wk after cell transfer. Treatment with BMS345541 reduced leukemia cell counts in blood (Fig. S8D) . Control mice treated with solvent containing solutions without BMS345541 died 5-7 wk after transplantation. Although a CD5 +
CD3
− population still could be detected in the blood and spleen of BMS345541-treated mice, the spleens of these mice were significantly smaller than those of the control-treated mice (Fig. S8 E and F) . Infiltration of leukemia cells in the marrow, mesenteric, and inguinal lymph nodes also was inhibited by treatment with BMS345541 (Fig.  S8F) . BMS345541 inhibited NF-κB nuclear translocation (Fig.  S8G) . The mice died 7-9 wk after cessation of therapy with BMS345541 because of recurrent disease (Fig. S8H) .
Discussion
We developed a mouse model for CLL by crossing iMyc Cα mice with Baff-Tg mice to generate Myc/Baff mice that develop a CLLlike B-cell malignancy. The leukemia developed by Myc/Baff mice resembles human CLL in several respects. The disease manifests a monoclonal lymphoproliferation of mature, well-differentiated CD5 + CD3 − B cells that cause lymphocytosis and diffuse infiltration of spleen, lymph nodes, and marrow. Unlike other mouse models of CLL (22, 23) , the leukemia that develops in Myc/Baff mice displays a male gender bias, similar to observations in human CLL. Conceivably, this mouse model might be used in future studies to interrogate the mechanism(s) accounting for the gender bias in human CLL, which remains unexplained.
The role of BAFF in Myc-induced leukemogenesis and progression relies in part on its ability to enhance B-cell resistance to apoptosis (Fig. 3) . In parallel, primary human CLL cells that expressed high levels of c-MYC had enhanced susceptibility to spontaneous apoptosis relative to that of CLL cells with low-level c-MYC expression, and this enhanced susceptibility to apoptosis could be offset by exogenous BAFF. On the other hand, we found that BAFF also up-regulated the expression c-MYC through activation of NF-κB in primary leukemia B cells (Fig. 4) ; this finding is different from the only reported link between BAFF and c-MYC expression in a Burkitt lymphoma cell line harboring the t (8;14) translocation that removes the endogenous c-MYC promoter (24) . Inhibition of IKK/NF-κB signaling either pharmacologically or by shRNA blocked the capacity of BAFF to up-regulate expression of c-MYC. Therefore, this study demonstrates that BAFF induces c-MYC expression through its endogenous promoter in CLL cells. However, we cannot exclude the contribution of other factors, such as alteration in expression of transcription factors or microRNAs (25) , which might be required for BAFF to enhance expression of c-MYC in CLL cells.
Although it is known that BAFF levels in plasma are not elevated in CLL patients relative to levels in normal individuals (26) , BAFF concentrates on the cell surface of NLC at much higher amounts than on CLL cells (19) . NLC are found in the spleen and secondary lymphoid tissues of CLL patients (20) , where they presumably protect CLL cells from apoptosis (19, 20) . However, the role played by NLC in CLL cell proliferation is not defined. Pseudofollicles inside secondary lymphoid tissues such as spleen and lymph node are the presumed sites for CLL cell proliferation and disease progression (27) . Therefore, it is conceivable that BAFF-mediated IKK/NF-κB activation can upregulate expression of c-MYC within these pseudofollicles and thereby contribute to disease progression. Moreover, primary CLL cells that express high levels of c-MYC had enhanced susceptibility to apoptosis relative to CLL cells that expressed low levels of c-MYC in vitro, suggesting that CLL cells with enhanced proliferative potential might have a greater dependency on microenvironmental survival factors, such as BAFF. Congruently, in vitro, CLL cells expressing high levels of c-MYC had a greater dependency on NLC, which could provide such survival signals, such as BAFF. In addition, NLC express high levels of APRIL (19, 20) , which also may induce activation of the canonical NF-κB pathway in CLL (8) . APRIL, together with other TNF family members that may be expressed in the proliferation centers (e.g., CD154/CD40L) (28) , also may play a role in enhancing the expression of c-MYC in CLL cells. In any case, this study demonstrates how BAFF, acting as an exogenous factor in the CLL microenvironment, can promote leukemogenesis in concert with c-MYC.
Finally, we noted heterogeneity of c-MYC expression in CLL (Fig. 5A) . Patients who had leukemia cells expressing high levels of c-MYC had a significantly higher risk for disease progression (Fig. 5B) . These patients' leukemia-cell samples did not have chromosomal translocations by G-banding analyses or features of Richter's transformation. CLL cells that had high levels of c-MYC expression were more dependent for survival on NLC, which express high levels of BAFF (19) (Fig. 5 D and E) . These studies therefore reveal not only an association between expression of c-MYC and aggressive disease in CLL but also a dynamic interplay between the expression of c-MYC and dependency on BAFF through activation of the canonical NF-κB pathway. We reason that inhibitors the canonical NF-κB pathway may be useful in the treatment of patients with CLL.
Methods

Mice. iMyc
Cα -Tg and Baff-Tg mice maintained in the C57BL/6 background were obtained from S. Janz (University of Iowa, Iowa City, IA) and L. Gorelik (Biogen Idec), respectively. Mice were housed under conventional barrier protection in accordance with University of California, San Diego (UCSD) and National Institutes of Health guidelines, and mouse protocols were approved by the UCSD Institutional Animal Care and Use Committee. Survival data were obtained by observing cohorts of 12 male mice of each genotype.
Primary Human CLL Cells. CLL cells were collected from blood samples of consenting patients who satisfied diagnostic and immunophenotypic criteria for CLL. Viability of CLL cells was assayed by double staining with 3, 3′-dihexyloxacarbocyanine iodide (DIOC6) and propidium iodide (PI). Expression of c-MYC in CLL cells was determined by immunoblotting, quantitated by Image J, and normalized to tubulin expression. BR3-Fc (Genentech) was used at 200 ng/mL, BAFF (Peprotech) at 200 ng/mL, and BMS345541 at 5 μM, unless otherwise noted.
